Investing.com -- Sana Biotechnology, Inc. (NASDAQ:SANA) shares soared by nearly 400% in premarket Tuesday trading following the company's announcement of encouraging results from its study concerning the treatment of type 1 diabetes.
The company's report detailed positive outcomes from the use of its hypoimmune technology in a first-in-human study. This technology allowed transplanted islet cells to produce insulin and avoid immune rejection without the need for immunosuppression.
The study's findings demonstrated that HIP-engineered primary pancreatic islet cells could evade immune detection, function effectively, and persist after being transplanted intramuscularly.
The implications of these results are profound and not limited to type 1 diabetes (T1D) treatment alone. Citi analyst Samantha Semenkow commented on the broader potential of the technology, stating, “the implications extend beyond T1D and islet cells though, and could potentially be applied broadly within the allogeneic field, including cell types such as glial cells, which Sana has also published preclinical data for.”
This breakthrough represents a significant milestone for Sana Biotechnology in its efforts to develop treatments for complex diseases using engineered cells. The company's success in this study could pave the way for further applications of its hypoimmune technology across various cell types and diseases, offering a new horizon in the field of allogeneic cell therapy.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.